Skip to main content Skip to main content
Go to homepage

FALCON Study - KL1333 in adults with mitochondrial dis

Efficacy of KL1333 in adult patients with primary mitochondrial disease

Description:

For complete details, please view the study on Clinicaltrials.gov

Interested in participating?
We are currently recruiting
Study Sponsor:

Abliva AB

Full IRB Study Title:
An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease
IRB Study ID:
2023-006
If you are interested in this study or have questions about your child's eligibility, please contact:

Josselyn Coppenger BSN, RN / 330-543-6164

Lead Investigator
Bruce H. Cohen, MD, FAAN

Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.